

8 August 2007

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
(NICE)
Peter House
Oxford Road
Manchester
M1 5AN



*Quarry House
Quarry Hill
Leeds
LS2 7UE*

Tel: [REDACTED]

Dear Carole

Single Technology Appraisal – Velcade (bortezomib) for multiple myeloma

Further to [REDACTED] letter to me of 6 August, I can confirm that the proposed adjustments to the Velcade responder scheme in terms of responder definition are acceptable to the Department of Health.

Yours sincerely

A large rectangular area that has been completely redacted, obscuring the signature and any text that might have been present.

[REDACTED]

[REDACTED]
Medicines, Pharmacy and Industry Group